Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.30 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30057341 | 1.00 | THRB (0.32) | THRBLMNATDP1SPHK2SPHK1 | |
| SCHEMBL3296001 | 1.00 | THRB (0.32) | THRBLMNATDP1SPHK2SPHK1 | |
| SCHEMBL18856153 | 1.00 | THRB (0.32) | THRBLMNATDP1SPHK2SPHK1 | |
| SCHEMBL1900467 | 1.00 | THRB (0.32) | THRBLMNATDP1SPHK2SPHK1 | |
| SCHEMBL10015241 | 1.00 | THRB (0.32) | THRBLMNATDP1SPHK2SPHK1 | |
| SCHEMBL3294716 | 1.00 | THRB (0.32) | THRBLMNATDP1SPHK2SPHK1 | |
| SCHEMBL16994826 | 1.00 | THRB (0.32) | THRBLMNATDP1SPHK2SPHK1 | |
| SCHEMBL28627915 | 1.00 | THRB (0.32) | THRBLMNATDP1SPHK2SPHK1 | |
| Tetrahydrofuran SCHEMBL29115159 | 0.89 | — | — | |
| SCHEMBL13312833 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119736265-B | Complex enzyme, co-immobilized enzyme and application thereof | 深圳瑞德林生物技术有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-119307463-B | Carbonyl reductase mutant and application thereof in synthesis of S-vitronectin | 中国科学院天津工业生物技术研究所 | 2025-04-15 | — | — | CN | claimed |
| CN-119736265-A | Complex enzyme, co-immobilized enzyme and application thereof | 深圳瑞德林生物技术有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119431292-A | High-purity S-configuration glass color factor and preparation method thereof | 东联际海(衢州)医药科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119307463-A | Carbonyl reductase mutant and application thereof in synthesis of S-vitronectin | 中国科学院天津工业生物技术研究所 | 2025-01-14 | — | — | CN | claimed |
| CN-119264090-A | Preparation method of glass color factor | 广州心丝美科学研究有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-118853790-A | Method for producing high-purity S-configuration hydroxypropyl tetrahydropyran triol by immobilized escherichia coli | 山东金城生物药业有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118345057-A | Carbonyl reductase mutant and application thereof in preparation of (S) -vitronectin | 山东金城生物药业有限公司 | 2024-07-16 | — | — | CN | claimed |
| CN-117229248-B | Method for preparing and purifying vitronectin by using solid alkali | 浙江晟格生物科技有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-117887679-B | Carbonyl reductase mutant and application thereof in preparation of (S) -vitronectin | 山东金城生物药业有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-113773291-B | Improved synthesis method of glass color factor of cosmetic active ingredient | 上海昕凯医药科技有限公司 | 2023-04-25 | — | — | CN | claimed |
| CN-115850223-A | Method for purifying and desalting vitriol reason | 湖北保乐生物医药科技有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-114835666-A | Continuous synthesis method of hydroxypropyl tetrahydropyrane triol | 天津泰普制药有限公司 | 2022-08-02 | — | — | CN | claimed |
| CN-113912578-A | Preparation method of hydroxypropyl tetrahydropyrane triol | 成都格纯生物医药有限公司 | 2022-01-11 | — | — | CN | claimed |
| CN-113773291-A | Improved synthesis method of vitronectin as effective component of cosmetics | 上海昕凯医药科技有限公司 | 2021-12-10 | — | — | CN | claimed |
| EP-1842527-B1 | Use of a C-glycoside compound as an agent for activating and regulating skin immunity | OREAL (FR) | 2019-06-26 | — | — | EP | claimed |
| US-20070265210-A1 | Administration of C-glycoside compounds for protecting and/or activating gammadeltaT lymphocytes | L'OREAL (FR) | 2007-11-15 | — | — | US | claimed |
| US-20070248556-A1 | Administration of C-glycoside compounds for activating and regulating cutaneous immunity | L'OREAL (FR) | 2007-10-25 | — | — | US | claimed |
| EP-1844757-A1 | Use of c-glycoside derivatives as an agent for protecting and/or activating gamma/delta t lymphocytes | L'Oréal (FR) | 2007-10-17 | — | — | EP | claimed |
| EP-1842527-A1 | Use of a C-glycoside compound as an agent for activating and regulating skin immunity | L'Oréal (FR) | 2007-10-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265210-A1 | Administration of C-glycoside compounds for protecting and/or activating gammadeltaT lymphocytes | NFATC1, EBP, CD4 | THRB 211/4885LMNA 1711/4885TDP1 1716/4885 |
| US-20070248556-A1 | Administration of C-glycoside compounds for activating and regulating cutaneous immunity | NFATC1, CCL11, CCR7 | THRB 4015/4885LMNA 4534/4885TDP1 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.